open access
Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection
Affiliations- Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland
- Department of Endocrinology, Oncological Endocrinology, Nuclear Medicine and Internal Medicine, University Hospital, Krakow, Poland
open access
Abstract
Introduction: The number of detected pancreatic neuroendocrine tumours (PanNETs) has been increasing over the last decades. Surgical resection remains the only potentially curative treatment, but the management is still controversial. This study aimed to compare patients after radical PanNET G2 resection to determine the most important predictive factors for relapse.
Material and methods: All patients with histologically confirmed PanNET G2 who underwent successful surgery between 2006 and 2020 with the intention of radical treatment were enrolled.
Results: In total, 44 patients were eligible for the analysis. The average follow-up was 8.39 ± 4.5 years. Disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumour was the tail of the pancreas (43.18%), especially in the subgroup with disease recurrence (56.25%). The smallest tumour diameter associated with the PanNET G2 recurrence was 22 mm. The relationship
between the largest dimension of the tumour with a division of < 4 cm vs. > 4 cm and the relapse was close to statistical significance. Recurrence was associated with a larger tumour size (p = 0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p = 0.036, V Cramer = 0.371) and disease relapse.
Conclusion: For the group of PanNET G2 patients after radical surgery, the overall risk of recurrence was 36.36%, with the highest rate in the first 5 years after surgery, but in individual cases it occurred significantly later, even 10 years after surgery. The most important predictive factors of the PanNET G2 recurrence was Ki-67 over 5.75% and size of tumour > 4 cm.
Abstract
Introduction: The number of detected pancreatic neuroendocrine tumours (PanNETs) has been increasing over the last decades. Surgical resection remains the only potentially curative treatment, but the management is still controversial. This study aimed to compare patients after radical PanNET G2 resection to determine the most important predictive factors for relapse.
Material and methods: All patients with histologically confirmed PanNET G2 who underwent successful surgery between 2006 and 2020 with the intention of radical treatment were enrolled.
Results: In total, 44 patients were eligible for the analysis. The average follow-up was 8.39 ± 4.5 years. Disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumour was the tail of the pancreas (43.18%), especially in the subgroup with disease recurrence (56.25%). The smallest tumour diameter associated with the PanNET G2 recurrence was 22 mm. The relationship
between the largest dimension of the tumour with a division of < 4 cm vs. > 4 cm and the relapse was close to statistical significance. Recurrence was associated with a larger tumour size (p = 0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p = 0.036, V Cramer = 0.371) and disease relapse.
Conclusion: For the group of PanNET G2 patients after radical surgery, the overall risk of recurrence was 36.36%, with the highest rate in the first 5 years after surgery, but in individual cases it occurred significantly later, even 10 years after surgery. The most important predictive factors of the PanNET G2 recurrence was Ki-67 over 5.75% and size of tumour > 4 cm.
Keywords
PanNET G2; pancreatic NET; neuroendocrine tumours; pancreatic tumours; disease recurrence; NET
About this articleTitle
Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection
Journal
Issue
Article type
Original paper
Pages
102-108
Published online
2024-02-21
Page views
256
Article views/downloads
179
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2024;75(1):102-108.
Keywords
PanNET G2
pancreatic NET
neuroendocrine tumours
pancreatic tumours
disease recurrence
NET
Authors
Helena Olearska
Anna Sowa-Staszczak
Karolina Morawiec-Sławek
Anna Kurzyńska
Magdalena Kolasa
Edyta Tkacz
Małgorzata Szumińska
Alicja Hubalewska-Dydejczyk
Marta Opalinska
References (26)- Stensbøl AB, Krogh J, Holmager P, et al. Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics (Basel). 2021; 11(11).
- Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011; 150(1): 75–82.
- Kurita Y, Hara K, Kuwahara T, et al. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol. 2020; 55(5): 543–552.
- Kos-Kudła B, Foltyn W, Malczewska A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]. Endokrynol Pol. 2022; 73(3): 387–454.
- Kurita Y, Hara K, Kuwahara T, et al. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol. 2020; 55(5): 543–552.
- Genç CG, Falconi M, Partelli S, et al. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. Ann Surg Oncol. 2018; 25(8): 2467–2474.
- Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res. 2017; 6: 663.
- Yang M, Ke NW, Zhang Yi, et al. TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. Medicine (Baltimore). 2015; 94(12): e660–82795.
- Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010; 23(6): 824–833.
- Pezzilli R, Partelli S, Cannizzaro R, et al. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. Adv Med Sci. 2016; 61(1): 147–153.
- Shyr BS, Shyr BU, Chen SC, et al. Impact of tumor grade on pancreatic neuroendocrine tumors. Asian J Surg. 2022; 45(12): 2659–2663.
- Kos-Kudła B, Rosiek V, Borowska M, et al. Pancreatic neuroendocrine neoplasms - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]. Endokrynol Pol. 2022; 73(3): 491–548.
- Ausania F, Senra Del Rio P, Gomez-Bravo MA, et al. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study. Pancreatology. 2019; 19(2): 367–371.
- Dąbkowski K, Starzyńska T. Management of small, asymptomatic, non-functioning pancreatic neuroendocrine tumours: follow-up, ablation, or surgery? Endokrynol Pol. 2023; 74(1): 25–30.
- Partelli S, Muffatti F, Rancoita PM, et al. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Dig Liver Dis. 2019; 51(5): 735–740.
- Li G, Tian ML, Bing YT, et al. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article. Medicine (Baltimore). 2019; 98(11): e14576.
- Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011; 150(1): 75–82.
- Milione M, Maisonneuve P, Pellegrinelli A, et al. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. Eur J Surg Oncol. 2019; 45(5): 755–760.
- Primavesi F, Klieser E, Cardini B, et al. ASSO pNEN Study Group. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group. Eur J Surg Oncol. 2019; 45(2): 198–206.
- Partelli S, Ramage JK, Massironi S, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne). 2020; 7: 598438.
- Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019; 19(12): 1029–1050.
- Arvold ND, Willett CG, Fernandez-del Castillo C, et al. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 83(3): e337–e343.
- Zhang P, Li YL, Qiu XD, et al. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study. World J Surg Oncol. 2019; 17(1): 66.
- Ziogas IA, Schmitz R, Moris D, et al. The Role of Surgery for Pancreatic Neuroendocrine Tumors. Anticancer Res. 2022; 42(2): 629–639.
- Orditura M, Petrillo A, Ventriglia J, et al. Pancreatic neuroendocrine tumors: Nosography, management and treatment. Int J Surg. 2016; 28 Suppl 1: S156–S162.
- Fahmy JN, Varsanik MA, Hubbs D, et al. Pancreatic neuroendocrine tumors: Surgical outcomes and survival analysis. Am J Surg. 2021; 221(3): 529–533.
